Context Therapeutics Inc. (CNTX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Context Therapeutics Inc. — 8-K Filing
# 🧾 What This Document Is This is a press release attached to an 8-K filing, which is a report of major events that shareholders should know about. The news here is that the U.S. Food and Drug Administration (FDA) has granted "Fast Track Designation" to Context Therapeutics' drug, CTIM-76. # 🏢 Wh
SEC filings
All filings →Insider trades
All insider trades →Context Therapeutics Inc. has no reported insider trades in the last 90 days.